新型冠状病毒肺炎抗病毒治疗现状及前景

doi:10.19803/j.1672-8629.2020.03.01

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (3): 129-135.
DOI: 10.19803/j.1672-8629.2020.03.01

新型冠状病毒肺炎抗病毒治疗现状及前景

田地, 王琳, 葛子若, 崔舒萍, 陈志海^*

首都医科大学附属北京地坛医院感染性疾病诊疗中心、新发突发传染病研究北京市重点实验室、感染病科国家临床重点专科,北京100015

收稿日期:2020-03-17 修回日期:2020-03-17 出版日期:2020-03-15 发布日期:2020-03-17
通讯作者: ^*陈志海,男,硕士,主任医师,教授·博导,新发突发传染病诊治。E-mail：chenzhihai0001@126.com
作者简介:田地,女,硕士,主治医师,感染性疾病。陈志海,主任医师,教授,医学硕士,博士生导师,首都医科大学附属北京地坛医院感染中心副主任,国家卫健委传染病标准专业委员会委员,中华预防医学会感染性疾病防控分会常务委员,中华医学会北京分会感染专业委员会副主任委员。致力各种急性传染病临床诊治研究30年,现场参与了2019年内蒙古鼠疫疫情的处置。牵头制定卫生行业标准1项,参与制定标准多项,参加10余个国家级指南或诊疗方案的制定。擅长各种急性传染病的诊断与治疗。为新型冠状病毒肺炎国家专家组、市级专家组成员,并领导新型冠状病毒肺炎病房一线工作。
基金资助:
国家科技重大专项（2018ZX09711003-014-003）:抗新型布尼亚病毒和狂犬病毒药物的临床研究; 新发突发传染病研究北京市重点实验室(09050703560908); 北京市医院管理局重点医学专业发展计划-新发突发传染病(ZYLX201602)

Present Situation and Prospect of Antiviral Treatments for COVID-19

TIAN Di, WANG Lin, GE Ziruo, CUI Shuping, CHEN Zhihai^*

Department of Infectious Diseases, the National Clinical Key Department of Infectious Diseases, Beijing Key Laboratory Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Received:2020-03-17 Revised:2020-03-17 Online:2020-03-15 Published:2020-03-17

摘要/Abstract

摘要： 2019年12月以来,湖北省武汉市陆续出现不明原因肺炎病例,2020年1月一种新型冠状病毒（2019-nCoV）被分离出来。随着新型冠状病毒肺炎（COVID-19）疫情蔓延,重症、危重症及死亡病例逐渐增多。我国《新型冠状病毒肺炎诊疗方案》中提出可试用洛匹那韦/利托那韦口服联合α-干扰素雾化、利巴韦林、磷酸氯喹、阿比多尔抗病毒,康复者血浆治疗重型及危重型患者。近日美国报道1例新型冠状病毒感染肺炎患者使用瑞德西韦治疗后得到明显改善。法匹拉韦也被认为有潜在疗效。抗病毒治疗是重症、危重症救治的关键。本文就新型冠状病毒肺炎抗病毒治疗可选药物现状及前景进行综述。

关键词: 新型冠状病毒肺炎, 抗病毒治疗

Abstract: In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei Province. In January 2020, a new type of coronavirus (2019-nCoV) was isolated. With the outbreak of COVID-19, the number of severe, critical and death cases is increasing gradually. In the diagnosis and treatment program of our country, the oral administration of lopinavir/ritonavir and the atomization of α-interferon were used, and ribavirin, chloroquine phosphate and abidol can also be used for antiviral treatment.The plasma of convalescent patients can be used for the treatment of severe and critical patients. Recently, a United States report that the first case of 2019-nCoV infection confirmed patient have been significantly improved after treatment with remdesivir. Fabiravir is also considered to have potential efficacy. Antiviral treatment is the key to the treatment of severe and critical diseases. In this paper, the present situation and prospect of selective antiviral treatments for COVID-19 is reviewed.

Key words: COVID-19, antiviral treatments

中图分类号:

R978.7

田地, 王琳, 葛子若, 崔舒萍, 陈志海. 新型冠状病毒肺炎抗病毒治疗现状及前景[J]. 中国药物警戒, 2020, 17(3): 129-135.

TIAN Di, WANG Lin, GE Ziruo, CUI Shuping, CHEN Zhihai. Present Situation and Prospect of Antiviral Treatments for COVID-19[J]. Chinese Journal of Pharmacovigilance, 2020, 17(3): 129-135.

参考文献

[1] Zhu N, Zhang D, Wang W.et al.A Novel Coronavirus from Patients with Pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733.
[2] Holshue ML, DeBolt C, Lindquist S, et al. First Case of2019 Novel Coronavirus in the United States[J]. N Engl J Med, 2020 Jan 31. DOI: 10.1056/NEJMoa2001191.
[3] Mulangu S, Dodd LE, Davey RT Jr, et al.A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics[J]. N Engl J Med, 2019, 381(24):2293-2303. doi: 10.1056/NEJMoa1910993.
[4] Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease[J]. mBio, 2018, 9(2). pii: e00221-18. doi: 10.1128/mBio.00221-18.
[5] Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses[J]. Sci Transl Med, 2017, 9(396). pii: eaal3653. doi: 10.1126/ scitranslmed.aal3653.
[6] de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection[J]. Proc Natl Acad Sci U S A, 2020 Feb 13. pii: 201922083. doi: 10.1073/pnas.1922083117.
[7] Brown AJ, Won JJ, Graham RL, et al.Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronav- iruseswith a highly divergent RNA dependent RNA polymerase[J]. Antiviral Res, 2019,169:104541. doi: 10.1016/j.antiviral.2019.104541.
[8] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Research, 2020 Feb 4. doi: 10. 1038/s41422-020-0282-0.
[9] 赵旭,周辛波,钟武,等.抗病毒药物—法匹拉韦[J].临床药物治疗杂志,2015,13(4): 16-20.
[10] 王先堃,孙娜,陈志海.法匹拉韦抗病毒治疗研究进展[J].中国新药杂志, 2019,28(15): 1824-1827.
[11] Agostini ML, Pruijssers AJ, Chappell JD, et al.Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance[J]. J Virol, 2019, 93(24):1-12.
[12] Warren TK, Wells J, Panchal RG, et al.Protection against filovirus diseases by a novel broad-spectrum nucleoside ana- logue BCX4430[J]. Nature, 2014, 508(7496):402-405.
[13] 国家卫生健康委员会办公厅,国家中医药管理局办公厅.《新型冠状病毒肺炎诊疗方案》(试行第七版)[EB/OL].(2020- 03-03)[2020-03-04]. http://www.gov.cn/zhengce/zhengceku/ 2020-03/04/content_5486705.htm.
[14] deWilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture[J]. Antimicrob Agents Chemother, 2014, 58(8):4875-4884.
[15] Chu CM, Cheng VC, Hung IF, et al.Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings[J]. Thorax, 2004, 59(3):252-256.
[16] Chan JF, Yao Y, Yeung M, et al.Treatment with lopinavir/riton- avir or interferon-β1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset[J]. J Infect Dis, 2015, 212(12):1904-1913.
[17] Arabi YM, Asiri AY, Assiri AM, et al.Treatment of Middle East Respiratory Syndrome With a Combination of Lopinavir/Ritonavir and interferon-β1b (MIRACLE Trial): Statistical Analysis Plan for a Recursive Two-Stage Group Sequential Randomized Controlled Trial[J]. Trials, 2020, 21(1):8.
[18] Sheahan TP, Sims AC, Leist SR, et al.Comparative therapeutic efficacy of remdesivir and combination lopinavir, and interferon beta against MERS-CoV[J]. Nat Commun, 2020 , 11(1):222.
[19] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro[J]. Cell Res, 2020 Feb 4. doi: 10.1038/s41422- 020-0282-0.
[20] Morra ME, Van Thanh L, Kamel MG, et al.Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis[J]. Rev Med Virol, 2018, 28(3):e1977.
[21] Leong HN, Ang B, Eamest A.Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003[J]. Trop Med Int Health, 2004 , 9(8):923-927.
[22] Stroher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome- related coronavirus is inhibited by Interferon-alpha[J]. J Infect Dis, 2004, 189(7):1164-1167.
[23] Stockman LJ, Bellamy R, Garner P.SARS: Systematic Review of Treatment Effects[J]. PLoS Med, 2006, 3(9):e343.
[24] Ferron F, Subissi L, Silveira De Morais AT, et al. Structural and Molecular Basis of Mismatch Correction and Ribavirin Excision From Coronavirus RNA[J]. Proc Natl Acad Sci U S A, 2018, 115(2):E162-E171.
[25] Akira S, Uematsu S, Takeuchi O.Pathogen Recognition and Innate Immunity[J]. Cell, 2006, 124(4):783-801.
[26] Chen F, Chan KH, Jiang Y, et al.In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral com- pounds[J].J Clin Virol, 2004, 31(1):69-75.
[27] Haagmans BL, Kuiken T, Martina BE, et al.Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques[J].Nat Med, 2004, 10(3):290-293.
[28] Omrani AS, Saad MM, Baig K, et al.Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection:a retrospective cohort study[J]. Lancet Infect Dis, 2014,14:1090-1095.
[29] Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with Middle East Respiratory Syndrome: A multicenter observational study[J]. Clin Infect Dis, 2019 Jun 25. pii: ciz544. doi: 10.1093/cid/ciz544.
[30] 郑阳,王全意.利巴韦林和干扰素-ɑ联合应用治疗中东呼吸综合征冠状病毒感染的生物信息学分析[J].中华流行病学杂志, 2016, 37(2) :291-293.
[31] Khamitov RA, Loginova Sla, Shchukina VN, et al.Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures[J]. Vopr Virusol, 2008, 53(4):9-13.
[32] 陈军,凌云,席秀红,等.洛匹那韦利托那韦和阿比多尔用于治疗新型冠状病毒肺炎的有效性研究[J].中华传染病杂志, 2020, 38( 00 ): E008-E008. DOI: 10.3760/cma.j.cn311365- 20200210-00050.
[33] Wang L, Shi W, Chappell JD, et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape[J]. J Virol, 2018, 92(10). pii: e02002-17. doi: 10.1128/JVI.02002-17.
[34] Niu P, Zhang S, Zhou P, et al.Ultrapotent human neutralizing antibody repertoires against Middle East respiratory syndrome coronavirus from a recovered patient[J]. J Infect Dis, 2018, 218(8):1249-1260. doi: 10.1093/infdis/jiy311.
[35] Chen Z, Bao L, Chen C, et al.Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset[J]. J Infect Dis, 2017, 215(12):1807-1815.
[36] Zhang S, Zhou P, Wang P, et al.Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein[J]. Cell Rep, 2018, 24(2):441-452.
[37] Coughlin MM, Babcook J, Prabhakar BS, et al.Human mono- clonal antibodies to SARS-coronavirus inhibit infection by different mechanisms[J]. Virology, 2009, 394(1):39-46.
[38] 卢帅,秦堃,谭文杰.中东呼吸综合征冠状病毒的实验室检测以及疫苗和治疗研究进展[J].中华实验和临床病毒学杂志, 2016, 30(6):582-586.
[39] Tian X, Li C, Huang A, et al.Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. Emerg Microbes Infect, 2020, 9(1): 382-385.
[40] Nie Y, Wang G, Shi X, et al.Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection[J]. J Infect Dis, 2004, 190(6):1119-26.

新型冠状病毒肺炎抗病毒治疗现状及前景

Present Situation and Prospect of Antiviral Treatments for COVID-19

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	葛子若, 田地, 王爱彬, 张婷玉, 任兴翔, 钱芳, 李兴旺, 陈志海. 干扰素雾化对新型冠状病毒肺炎的临床治疗分析[J]. 中国药物警戒, 2022, 19(7): 733-739.
[2]	王铁柱. 硫酸羟氯喹致视觉损害不良反应信号检测与分析[J]. 中国药物警戒, 2022, 19(6): 657-660.
[3]	赵暄, 郭婧, 梅隆, 张威. 自动发药系统对门诊药房工作效率和新型冠状病毒肺炎疫情防控的影响分析[J]. 中国药物警戒, 2022, 19(5): 564-567.
[4]	吴作敏, 杨娟, 王隆隆, 王瑞. 黄芪-防风药对治疗新型冠状病毒肺炎的网络药理学研究[J]. 中国药物警戒, 2022, 19(4): 395-399.
[5]	杨帆, 马海平, 尤萌茹, 廖沙, 刘兰, 朱军. 456例新型冠状病毒肺炎患者抗病毒药物应用分析[J]. 中国药物警戒, 2022, 19(4): 413-416.
[6]	郭军, 任丹, 叶龙, 赵荣香, 王宇, 余静. 华法林片致儿童非创伤性自发性肌肉出血1例分析[J]. 中国药物警戒, 2022, 19(3): 339-341.
[7]	熊婧, 刘毅, 刘朝霞, 李婕, 张才煜, 武香香, 何兰. 抗新型冠状病毒肺炎候选药物利托那韦首批国家对照品研制[J]. 中国药物警戒, 2022, 19(2): 137-141.
[8]	李天钰, 贾翌江, 王玉记, 王金辉, 李烨. 新型冠状病毒肺炎治疗药物研究进展[J]. 中国药物警戒, 2022, 19(11): 1266-1271.
[9]	赵喆, 张清, 葛子若, 张伟, 陈志海. 小分子抗新型冠状病毒药物的突破性进展[J]. 中国药物警戒, 2022, 19(1): 1-6.
[10]	熊婧, 严菁, 刘毅, 刘阳, 何兰. 抗新型冠状病毒候选药物法维拉韦首批国家对照品的研制[J]. 中国药物警戒, 2022, 19(1): 52-56.
[11]	赵暄, 郭婧, 任爽, 甄健存. 新型冠状病毒肺炎疫情防控常态化下门诊药房日常防控措施及工作模式探索[J]. 中国药物警戒, 2022, 19(1): 100-102.
[12]	丛端端, 赵飞, 薛薇, 李可欣, 胡欣. 基于药物临床试验质量管理规范对新型冠状病毒肺炎相关临床研究的思考和建议[J]. 中国药物警戒, 2021, 18(2): 101-104.
[13]	吴菲, 李民, 方玉婷, 陈泳伍, 沈爱宗. 洛匹那韦利托那韦治疗新型冠状病毒肺炎的不良反应主动监测研究[J]. 中国药物警戒, 2021, 18(2): 105-109.
[14]	吕强, 阎嘉阳, 张旺喆麒, 叶小飞, 郭晓晶. 抗新型冠状病毒肺炎药物磷酸氯喹的安全性分析[J]. 中国药物警戒, 2021, 18(2): 110-114.
[15]	刘枭, 徐银莹, 姜孙旻, 许云. 基于网络药理学和分子对接探讨疏风解毒胶囊治疗新型冠状病毒肺炎可能的作用机制[J]. 中国药物警戒, 2021, 18(2): 115-120.